Citigroup
QNCX icon

Citigroup’s Quince Therapeutics QNCX Stock Holding History

Citigroup’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32
Closed -$21.7K – 6308
2025
Q4 		$21.7K Buy
+32
New +$16.1K ﹤0.01% 4845
2025
Q1 		– Sell
-26
Closed -$9.66K – 5889
2024
Q4 		$9.66K Sell
26
-60
-70% -$18K ﹤0.01% 5385
2024
Q3 		$13.3K Buy
86
+60
+231% +$8.6K ﹤0.01% 5248
2024
Q2 		$3.87K Hold
26
– – ﹤0.01% 5285
2024
Q1 		$5.47K Hold
26
– – ﹤0.01% 5312
2023
Q4 		$5.42K Hold
26
– – ﹤0.01% 5320
2023
Q3 		$5.79K Hold
26
– – ﹤0.01% 4683
2023
Q2 		$7.77K Hold
26
– – ﹤0.01% 5115
2023
Q1 		$8.06K Hold
26
– – ﹤0.01% 4821
2022
Q4 		$3.29K Sell
26
-2
-7% -$334 ﹤0.01% 5125
2022
Q3 		$7K Sell
28
-1
-3% -$381 ﹤0.01% 5120
2022
Q2 		$13K Sell
29
-15
-34% -$10.6K ﹤0.01% 5242
2022
Q1 		$54K Sell
44
-38
-46% -$51.7K ﹤0.01% 4695
2021
Q4 		$207K Sell
82
-197
-71% -$1.2M ﹤0.01% 4344
2021
Q3 		$5.12M Sell
279
-6
-2% -$95.4K ﹤0.01% 1816
2021
Q2 		$3.02M Sell
285
-48
-14% -$402K ﹤0.01% 2334
2021
Q1 		$2.4M Buy
333
+312
+1,486% +$2.24M ﹤0.01% 2383
2020
Q4 		$118K Buy
21
+16
+320% +$142K ﹤0.01% 5405
2020
Q3 		$45K Sell
5
-66
-93% -$600K ﹤0.01% 5671
2020
Q2 		$654K Buy
71
+54
+318% +$495K ﹤0.01% 3982
2020
Q1 		$158K Buy
17
+5
+42% +$49.4K ﹤0.01% 4933
2019
Q4 		$130K Buy
12
+11
+1,100% +$66.4K ﹤0.01% 5525
2019
Q3 		$4K Sell
1
-3
-75% -$18.5K ﹤0.01% 7402
2019
Q2 		$34K Buy
+4
New +$23.9K ﹤0.01% 6780

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citigroup's QNCX Position: Q1 2026 in Review

Citigroup sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 32 shares — an estimated $21.7K sold.

Citigroup first reported a position in QNCX in Q2 2019 and held it in 24 quarters. The position peaked at $5.12M in Q3 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Citigroup reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 32 Quince Therapeutics shares in Q1 2026, an estimated $21.7K.
  • Citigroup first reported a position in Quince Therapeutics in Q2 2019 and held it in 24 quarters.
  • Citigroup's Quince Therapeutics position peaked at $5.12M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.